QL1706 + short chemo for early triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new immunotherapy drug (QL1706) combined with a short course of common chemotherapy (anthracyclines or taxanes) for people with early-stage triple-negative breast cancer. The goal is to see if this combination is safe and helps shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70 with newly diagnosed breast cancer that is triple-negative (no hormone or HER2 receptors).
- Your cancer is early-stage but has a tumor larger than 2 cm and may have spread to nearby lymph nodes (stages T2–T4, N0–N3).
- You have not received any chemotherapy or immunotherapy for this breast cancer before.
- You are generally healthy enough to be up and active (ECOG score 0 or 1).
- You must be willing to use effective birth control during the study and for 6 months after, and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new drug called QL1706 (an immunotherapy that helps your immune system fight cancer) combined with standard chemotherapy before surgery. The goal is to see if this combination can shrink or eliminate the tumor more effectively in early-stage triple-negative breast cancer, potentially improving your long-term outcome.
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests an experimental drug called QLC5513, either by itself or combined with another drug (QL1706), for people with triple-negative breast cancer that has continued to grow despite prior treatment. The goal is to see if this new approach can shrink tumors or slow the cancer's progression, and it might be an option if standard treatments have stopped working.
Hear when a new TNBC, Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.